Continuous Glucose Monitors and Automated Insulin Dosing Systems in the Hospital Consensus Guideline. by Galindo, Rodolfo J et al.
Galindo                                                                                                                                                 Page 1 of 81 
Continuous Glucose Monitors and Automated Insulin Dosing Systems in the Hospital 1 
Consensus Guideline 2 
 3 
Rodolfo J. Galindo, MD, FACE1, Guillermo E. Umpierrez, MD, CDE1, Robert J. Rushakoff, MD2, 4 
Ananda Basu, MD, FRCP3, Suzanne Lohnes, MA, RN, CDCES, CPT4, James H. Nichols, PhD, 5 
DABCC, FAACC5, Elias K. Spanakis, MD6,7, Juan Espinoza, MD, FAAP8, Nadine E. Palermo, DO9, 6 
Dessa Garnett Awadjie, MSN, FNP10, Leigh Bak, MSN, APRN, ACNS-BC, CDCES11, Bruce 7 
Buckingham, MD12, Curtis B. Cook, MD13, Guido Freckmann, MD14, Lutz Heinemann, PhD15, 8 
Roman Hovorka, PhD, FMedSci16, Nestoras Mathioudakis, MD, MHS17, Tonya Newman, JD18, 9 
David N. O’Neal, MD, FRACP19, Michaela Rickert, MS, PA-C, RDN, CDE20, David B. Sacks, MB, 10 
ChB, FACP, FRCPath21, Jane Jeffrie Seley, DNP, MPH, MSN, GNP, RN, BC-ADM, CDCES, CDTC, 11 
FADCES, FAAN22, Amisha Wallia, MD, MS23, Trisha Shang, BA24, Jennifer Y. Zhang, BA24, Julia 12 
Han, BA24, David C. Klonoff, MD, FACP, FRCP (Edin), Fellow AIMBE25 13 
 14 
Affiliations: 15 
1Emory University School of Medicine, Atlanta, GA, USA 16 
2University of California, San Francisco, San Francisco, CA, USA 17 
3University of Virginia School of Medicine, Charlottesville, VA, USA 18 
4University of California San Diego Medical Center, La Jolla, CA, USA 19 
5Vanderbilt University Medical Center, Nashville, TN, USA 20 
6University of Maryland School of Medicine, Baltimore, MD, USA 21 
7Division of Endocrinology, Baltimore Veterans Affairs Medical Center, Baltimore, MD, USA 22 
8Children’s Hospital Los Angeles, Los Angeles, CA, USA 23 
9Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA 24 
10New York University Langone Health, New York, NY, USA 25 
11Yale New Haven Hospital, New Haven, CT, USA 26 
12Stanford University School of Medicine, Palo Alto, CA, USA 27 
13Mayo Clinic Arizona, Scottsdale, AZ USA 28 
14Institute for Diabetes-Technology GmbH, Ulm, Germany 29 
15Science Consulting in Diabetes GmbH, Neuss, Germany 30 
16University of Cambridge, Cambridge, UK 31 
17Johns Hopkins University School of Medicine, Baltimore, MD 32 
18Neal, Gerber and Eisenberg LLP, Chicago, IL, USA 33 
19University of Melbourne Department of Medicine, St. Vincent’s Hospital, Fitzroy, Victoria, 34 
Australia 35 
20Oregon Health and Sciences University, Portland, OR, USA 36 
21National Institutes of Health, Bethesda, MD, USA 37 
22Weill Cornell Medicine, New York, NY, USA 38 
Galindo                                                                                                                                                 Page 2 of 81 
23Northwestern University Feinberg School of Medicine, Chicago, IL, USA 39 
24Diabetes Technology Society, Burlingame, CA, USA 40 
25Mills-Peninsula Medical Center, San Mateo, CA, USA 41 
 42 
Corresponding Author:  43 
David C. Klonoff, MD, FACP, FRCP (Edin), Fellow AIMBE 44 
Mills-Peninsula Medical Center, San Mateo, CA, USA 45 
Address: 100 South San Mateo Drive Room 5147, San Mateo, CA 94401  46 
Phone Number: 1 (650) 218-1142 47 
Email: dklonoff@diabetestechnology.org 48 
 49 




This article is the work product of the Continuous Glucose Monitor and Automated Insulin 54 
Dosing Systems in the Hospital Consensus Guideline Panel, that was organized by Diabetes 55 
Technology Society and met virtually on April 23, 2020. The guideline panel consisted of 24 56 
international experts in the use of CGMs (continuous glucose monitors) and AID (automated 57 
insulin dosing) systems representing  adult endocrinology, pediatric endocrinology, obstetrics 58 
and gynecology, advanced practice nursing, diabetes care and education, clinical chemistry, 59 
bioengineering, and product liability law. The panelists reviewed the medical literature 60 
pertaining to five topics: 1) continuation of home CGMs after hospitalization, 2) initiation of 61 
CGMs in the hospital, 3) continuation of AID systems in the hospital, 4) logistics and hands-on 62 
care of hospitalized patients using CGMs and AID systems, and 5) data management of CGMs 63 
and AID systems in the hospital. The panelists then developed three types of recommendations 64 
for each topic, including clinical practice (to use the technology optimally), research (to improve 65 
the safety and effectiveness of the technology), and hospital policies (to build an environment 66 
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for facilitating use of these devices) for each of the five topics.  The panelists voted on 78 67 
proposed recommendations.  Based on the panel vote, 77 recommendations were classified as 68 
either strong or mild. One recommendation failed to reach consensus. Additional research is 69 
needed on CGMs and AID systems in the hospital setting regarding device accuracy, practices 70 
for deployment, data management, and achievable outcomes. This guideline is intended to 71 
support these technologies for the management of hospitalized patients with diabetes.   72 
 73 
Introduction 74 
Continuous glucose monitors (CGMs) are becoming an important technology for improving 75 
glycemic outcomes in diabetes. The opportunity for a patient (or by way of wireless 76 
communication, a caregiver or relative) to see real-time glucose concentrations tested 77 
automatically and continuously is transforming the practice of diabetes care. Recent 78 
generations of these devices offer improved accuracy, smaller form factors, extended sensor 79 
life, and new data presentation software for translating data into increasingly useful metrics on 80 
various mobile platforms.  Some new factory-calibrated CGMs have eliminated the need for 81 
finger-stick blood glucose testing by users (except at certain times per individual product 82 
instructions, such as soon after insertion, when there appear to be errors or no readings at all, 83 
when the CGM value does not match how the patient feels, or when an  icon indicates the need 84 
for testing blood glucose.)  85 
CGMs for monitoring glucose concentrations and automated insulin dosing (AID) systems, that 86 
contain a CGM controlling a continuous subcutaneous insulin infusion (CSII) system (also known 87 
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as an insulin pump), are cleared (class II) or approved (class III) by the United States Food and 88 
Drug Administration (FDA) for home use (by prescription) by people who have diabetes. 89 
However, many clinicians believe that CGMs have the potential to be utilized by hospitalized 90 
patients in a variety of situations.  91 
Escalating interest in utilizing CGMs and AID systems in a hospital setting has resulted in a need 92 
for guidance on the continuation of these technologies in the hospital setting. This interest has 93 
been stimulated by four trends in the application of CGM technology, including: 1) 94 
improvements in the technology and human factors of CGMs, 2) an increasing number of 95 
patients wearing these devices in ambulatory settings, 3) growing interest by clinicians to 96 
understand and interpret their hospitalized patients’ glucose concentrations, and 4) an 97 
accumulation of published reports describing use of these products in investigational settings.  98 
Diabetes Technology Society (DTS) previously organized guidance on the use of CGMs in the 99 
hospital as “Consensus Statement on Inpatient Use of Continuous Glucose Monitoring”1, 100 
published in 2017. Because of recent increasing interest in this topic, coupled with advances in 101 
technology, DTS recognized a need for an updated consensus guideline on the use of CGMs and 102 
AID systems in an acute care setting.    103 
On April 23, 2020, DTS, led by Dr. David Klonoff, convened the Continuous Glucose Monitor and 104 
Automated Insulin Dosing Systems in the Hospital: Consensus Guideline Panel. This 105 
international panel consisted of experts in diabetes technology from the United States, Europe, 106 
and Australia. The purpose of this meeting was to provide guidance for clinicians on how and 107 
when to best use both subcutaneous CGMs and AID systems, as well as to promote clinical 108 
research utilizing these devices.   109 
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The panel was planned in late 2019 before the first case of Coronavirus Disease 2019 (COVID-110 
19) was reported. Two weeks prior to the panel meeting, two CGM companies announced that 111 
during the pandemic, the FDA had told them that the Agency would not object if these 112 
companies provided devices and technical support to hospitals who ordered CGMs for off label 113 
use.2,3 Because some healthcare systems were interested in validating CGMs for use in their 114 
hospitals to preserve PPE supplies and to minimize patient/provider contact, there was 115 
additional urgency for the panel to develop new clinical guidance. Panelists discussed how the 116 
pandemic has impacted inpatient glucose monitoring and how an urgent need has arisen for 117 
alternative approaches to this monitoring.4 The traditional approach of testing capillary blood 118 
glucose (BG) every 1-2 hours in patients who are receiving intravenous insulin in an intensive 119 
care unit (ICU) as well as frequent BG testing in non-ICU wards for patients receiving 120 
subcutaneous insulin is not workable during the pandemic. Other methods are needed to 121 
decrease nurse contact with the patient for assisted monitoring of BG (AMBG)5 in order to: 1) 122 
decrease risk of contagion from exposure to patients, 2) save time from donning and doffing 123 
personal protective equipment (PPE) wherever possible, and 3) preserve limited supplies of 124 
PPE4. Despite limited guidance,  established studies, or widespread support from the clinical 125 
community to use CGMs in acute care6, some HCPs in the hospital diabetes community have 126 
recently begun to prescribe CGMs in the hospital setting for investigational or off-label use for 127 
COVID-19 patients.7 128 
The Continuous Glucose Monitors and Automated Insulin Dosing Systems in the Hospital 129 
Consensus Guideline Panel included professionals from a variety of backgrounds. Members 130 
included experts in the use of CGMs from adult endocrinology, pediatric endocrinology, 131 
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obstetrics and gynecology, advanced practice nursing, diabetes care and education, clinical 132 
chemistry, bioengineering, and product liability law. The expert panel included representatives 133 
from academia and government and observers from government (FDA), and industry (Abbott 134 
Diabetes Care, Dexcom, Glytec, Medtronic, and Roche Diagnostics). One member represented 135 
the College of American Pathologists, one represented the Endocrine Society, and one 136 
represented the Association of Diabetes Care and Education Specialists. 137 
The expert panel discussed the following five topics: 1) continuation of home CGMs after 138 
hospitalization, 2) initiation of CGMs in the hospital, 3) continuation of AID systems in the 139 
hospital, 4) logistics and hands-on care of hospitalized patients using CGMs and AID systems, 140 
and 5) data management of CGMs and AID systems in the hospital. (Table 1) Panelists reviewed 141 
available evidence on the inpatient use of diabetes technology, and discussed potential 142 
opportunities, potential barriers, and recommendations associated with the use of these 143 
devices in the hospital setting.  144 
Recommendations were proposed by the panelists and then reviewed by the entire panel for 145 
favorability. Recommendations receiving at least 80% favorable votes were classified as strong 146 
recommendations, proposals receiving 60-79% favorable votes were classified as mild 147 
recommendations, and proposals receiving less than 60% favorable votes were classified as 148 
recommendations which failed to receive consensus support.    149 
For each of the five topics of this guideline (Table 1), six categories of recommendations (two 150 
for clinical practice, two for future research, and two for hospital policies) were developed for 151 
the main stakeholders of CGM and AID system technology in the hospital. These types of 152 
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recommendations included: 1) and 2) strong and mild recommendations that clinicians 153 
(healthcare professionals, HCPs or nursing) should do to utilize  the technology optimally, 3) 154 
and 4) strong and mild recommendations that researchers and manufacturers need to do to 155 
improve the safety and effectiveness of the technology, and 5) and 6) strong and mild 156 
recommendations that hospitals need to do to build an environment for facilitating use of these 157 
devices.  We define “should” as a statement of good practice and “need” as a necessary step to 158 
ensure patient safety or proper fulfillment of a procedure.  These recommendations are 159 
intended to promote the best use of CGMs and AID systems in the hospital.  160 
Background 161 
CGMs were developed for the outpatient setting, and their transition for use in hospitals has 162 
been the subject of ongoing scholarship, research, and consensus guidelines. The first CGM 163 
became commercially available in 19998. CGM technology has greatly improved since then and 164 
several revolutionary developments in CGM technology have taken place over the past 5 years. 165 
These advances have all significantly reduced patients’ burden of diabetes care. The result has 166 
been improved patient satisfaction and self-care behaviors, increased clinician awareness, and 167 
a significant increase in CGM adoption, mostly by patients with Type 1 diabetes mellitus 168 
(T1DM), but also in some patients with Type 2 diabetes mellitus (T2DM)9. Software for 169 
analyzing continuous glucose data streams has permitted the development of new CGM-based 170 
glycemic metrics, which compared to hemoglobin A1c, illustrate multidimensional patterns of 171 
glycemia more directly and with greater granularity10. Improvements in CGM technology have 172 
also permitted integration with CSII systems to create AID systems. With the increasing 173 
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popularity of AID systems that depend on CGMs, hospital HCPs will increasingly encounter 174 
patients who will want to utilize their CGMs and AID systems for inpatient diabetes care. 175 
AID systems are becoming more advanced and are more frequently utilized for outpatients to 176 
successfully achieve glycemic outcomes in diabetes by facilitating increased time in range (TIR) 177 
and decreased time in hypo- and hyperglycemia. Two AID systems are currently cleared or 178 
approved by the FDA for home use in people with diabetes: 670G (Medtronic, Northridge, 179 
California) and Tandem Control IQ (Tandem Diabetes Care, Inc., San Diego, California). Some 180 
patients utilizing these AID systems and/or their physicians wish to continue the AID systems 181 
even during a hospitalization, believing that the benefits of commercial AID systems outweigh 182 
potential risks in this setting and noting that product use would not be off label if a patient is 183 
self-managing using the device even if the patient is in the hospital while doing it. 184 
CGM sensors can be invasive (intravascular blood sampling or sensing devices that remove 185 
blood), minimally invasive (subcutaneous placement of a sensor), or non-invasive (transdermal 186 
CGMs that do not puncture the skin). They are measuring in different compartments, which can 187 
lead to different values.11  The frequency of receiving a signal by a CGM ranges from every 1 to 188 
every 15 minutes, most commonly every 5 minutes. Invasive CGMs that are intended only for 189 
hospital use include two systems cleared by the FDA. They are 1) the GlucoScout (International 190 
Biomedical, Austin, TX)12 and 2) the OptiScanner 5000 (OptiScan Biomedical Corporation, 191 
Hayward, California)13. Both devices track glycemic patterns of blood that is withdrawn from 192 
the venous system of adults13. In Europe, four CGMs have been CE Marked for measuring 193 
venous blood in hospitalized patients: 1) GlucoClear (Edwards Life Sciences, Irvine, California)14, 194 
2) Glysure System (Glysure, Abingdon, Oxfordshire, UK)15, 3) Eirus (Maquet Getinge Group, 195 
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Rastatt, Germany)16, and 4) Optiscanner 500013. The Optiscanner 5000 has received FDA 196 
clearance, but the Glucoclear, Glysure System, and Eirus products all have not received FDA 197 
clearance. The Glucoclear and Eirus products have been discontinued, and Glysure Ltd. went 198 
out of business in 2018. The Optiscanner 5000 is available in the US and Europe. One CGM with 199 
a subcutaneous sensor was available in Europe for measuring glucose in hospitalized patients: 200 
Sentrino Continuous Glucose Management System (Medtronic, Northridge, California)17. 201 
However, at this time Sentrino is not a commercial product. There are no commercially 202 
available non-invasive CGMs in the United States. 203 
In the hospital special issues can arise that can impair proper function of CGMs. No CGM is 204 
labeled to allow for exposure to X-Rays, CT scans, magnetic resonance imaging (MRIs), 205 
diathermy, radiation therapy, or other types of radiation. Typically, the device is removed or 206 
covered with a lead shield during these procedures. Some sites have covered their CGMs with a 207 
lead shield and have not reported adverse events. Emerging data suggests there may be no 208 
need for removal of the Dexcom G6 sensor (Dexcom, San Diego, California) during X-rays, CT 209 
scans, radiation therapy, or when electrocautery is used during surgical procedures.18–20  There 210 
were no data errors observed when FreeStyle Libre Pro sensor was exposed to chest X-rays, 211 
computed tomography (CT), radiotherapy (RT), and magnetic resonance imaging (MRI).21 The 212 
panel expected that each manufacturer will continue to determine and report the impact of 213 
imaging studies and electrocautery on their particular devices.  214 
An attractive feature of CGMs is that they can measure glucose concentrations automatically 215 
and sound an alarm for readings that are outside of a prespecified safe target range. Table 2 216 
contains a list of the five currently available subcutaneous home-use CGMs that have the 217 
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potential for hospital use: FreeStyle Libre 14 day system22 , FreeStyle Libre 223 (both Abbott 218 
Diabetes Care, Chicago, Illinois), Dexcom G624, Medtronic Guardian Sensor 325 (Medtronic 219 
Diabetes, Northridge, California), and Eversense (Senseonics, Inc., Germantown, Maryland) 26. 220 
This table includes the devices’ glucose sensing methods, technical features, and presence of 221 
interference from chemical substances.  222 
Continuation of home Continuous Glucose Monitors after hospitalization  223 
Chair: Robert J. Rushakoff, M.D. 224 
University of California, San Francisco, San Francisco, California, USA 225 
POTENTIAL OPPORTUNITIES 226 
Patient Considerations 227 
Standalone CGMs and AID systems are typically used in the outpatient setting. If a patient 228 
wearing either of these technologies is hospitalized, then policies are needed to continue these 229 
technologies. Some hospitals have policies for removing personal use devices like CGMs, CSII 230 
systems and AID systems from patients when they are admitted. It is within the FDA’s 231 
authorized use for a patient to use their own device for self-management while in a hospital.   232 
What is not authorized is when a hospital wants to use the CGM for their own testing purposes 233 
as well as in patients who do not have diabetes.  234 
This section focuses on continuing a CGM already started before a patient arrives at the 235 
hospital and a subsequent section focuses on initiating a CGM in the hospital. Anyone with 236 
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diabetes who is using a CGM and who is not cognitively impaired is a candidate to continue 237 
with this device in the hospital.  238 
Benefits of CGMs 239 
Several studies have demonstrated that CGMs in ambulatory settings improve patients’ 240 
satisfaction,38,39 as well as control (e.g. better TIR and time in hypo- and hyperglycemia)40,41. 241 
Continuation of an outpatient CGM during a hospitalization could improve patient satisfaction 242 
and efficacy of glycemic monitoring by assisting the patient and the hospital staff to identify 243 
glucose patterns, predict future glycemia with trend arrows and rate-of-change42, and 244 
potentially prevent severe hypo- and hyperglycemic events.43  This would be particularly 245 
relevant if staffing shortages exist or a patient is no longer aware of hypoglycemia. Accordingly, 246 
asking patients to remove their CGMs in the hospital could potentially contribute to decreased 247 
patient satisfaction and quality of care. CGM use in ICU and non-ICU settings has several 248 
superior features over intermittent point of care (POC) testing for glucose monitoring during 249 
continuous insulin infusion and subcutaneous insulin therapy, and possibly is a safer and less 250 
costly approach that can reduce workload. Additionally, CGM technology could potentially 251 
replace many uses of POC capillary BG testing in the hospital. 43 However, if CGM readings turn 252 
out to be inaccurate, then more confirmatory testing would be needed and that could increase 253 
workload.  254 
Pregnancy 255 
The use of CGMs in pregnant patients with T1DM has been associated with improvement in 256 
both maternal and fetal outcomes in five areas, including: 1) time in glycemic target range 257 
Galindo                                                                                                                                                 Page 12 of 81 
without increase in hypoglycemia, 2) lower incidence of large for gestational age babies, 3) 258 
fewer neonatal intensive care unit admissions, 4) reduced neonatal hypoglycemia, and 5) 259 
decreased LOS.44,45 The use of CGMs in pregnancy is considered off-label in the US, but not in 260 
Europe. In recent years, patients and HCPs have identified real time continuous glucose 261 
monitoring as a helpful adjunct. Although there is ongoing interest in the use of CGMs in 262 
pregnancy, there is limited data about its use in the acute care setting. If an HCP intends to use 263 
such a device, then it would be important to avoid placing it near areas of potential obstetric 264 
surgery.  265 
 266 
POTENTIAL BARRIERS 267 
Studies on substances that interfere with current subcutaneous CGMs are shown in Table 2. 268 
The panel agreed that CGM results should be interpreted cautiously in patients using select 269 
drugs known to cause interference with CGM sensing technologies. For these situations, 270 
panelists recommended using more accurate glucose testing, such as laboratory analyzers or 271 
AMBG5 using hospital BGMs (which, unlike home-use BGMs, require special cleaning and 272 
disinfection procedures). Even though these devices are factory-calibrated and a limited set of 273 
studies have reported acceptable accuracy in critically ill patients46, several potential scenarios 274 
in the hospital (e.g., interfering substances, hypoxia, acidosis, and hypotension) would require 275 
very careful use of this technology. The panel did not feel that current CGMs can now replace 276 
capillary POC finger stick monitoring or other FDA cleared methods for monitoring BG in the 277 
hospital.  278 
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Recommendations for Continuation of home Continuous Glucose Monitors after 279 
hospitalization   280 
Clinical Practice 281 
Strong Recommendations 282 
• HCPs should consult with an inpatient diabetes team if available, when continuing or 283 
initiating a CGM or AID system. 284 
• HCPs should avoid relying on CGM data for glycemic management decisions in patients 285 
with severe hypoglycemia or hyperglycemia (i.e. BG < 40 mg/dL or >500 mg/dL).  286 
• HCPs should avoid using CGMs for management of 1) diabetic ketoacidosis until glucose 287 
is in the CGM measurement range, and then CGMs should be used adjunctively or 2) 288 
situations with rapidly changing glucose levels and fluid/electrolyte shifts. 289 
• HCPs should avoid continuing or initiating CGMs to patients with skin infections near the 290 
sensor site or placing sensors in areas with significant edema as well as patients treated 291 
with vasoactive agents or poor tissue perfusion. 292 
• HCPs should use a CGM checklist for elective procedures during the pre-operative visits 293 
to ensure proper documentation of devices and real time data reporting. 294 
• HCPs should advise pregnant women to continue the use of a CGM during a 295 
hospitalization to identify glucose trends and prevent hypo- or hyperglycemia. 296 
• HCPs should instruct patients to bring supplies with them to the hospital for the 297 
duration of any pre-planned admission or elective procedures. 298 
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• HCPs should check capillary BG or serum BG concentrations after procedures for non-299 
critically ill patients and venous/arterial blood for critically ill patients to ensure the 300 
patient’s CGM is functioning properly.   301 
• HCPs should use trend arrows and rate of change to help prevent extreme glycemic 302 
excursions and (when a CGM is used adjunctively) to help determine when a BG test is 303 
required.   304 
• HCPs should set alarm thresholds for inpatient glycemic targets, such as predicting 305 
hypoglycemia (typically BG < 80-85 mg/dL) or predicting hyperglycemia. 306 
• Nursing should document CGM and/or CSII system information in the electronic health 307 
record (EHR) for all admissions or elective procedures. 308 
Research 309 
Strong Recommendations  310 
• Researchers need to provide more data to support definitive recommendations on 311 
improved outcomes for continuation of home/ambulatory CGM use after 312 
hospitalization. 313 
• Researchers need to conduct studies on the roles of CGM and POC BG testing and 314 
identify the optimal features of telemetry to inform nursing staff about actionable CGM 315 
patterns. 316 
• Researchers need to perform further studies to assess the accuracy of CGMs during 317 
pregnancy, labor & delivery, and the peripartum period. 318 
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• Researchers need to study the impact of lag time on glucose measurements (i.e. 319 
situations with rapid changes in the glucose concentration) in the hospital. 320 
Hospital Policies 321 
Strong Recommendations 322 
• Hospitals need to develop standard CGM data reports and workflows. 323 
• Hospitals need to implement policies for testing capillary BGs and calibrating CGMs if 324 
the CGM requires calibration. 325 
• Hospitals need to develop a system for automatic staff notification for CGM alarms that 326 
predict impending or current hypoglycemia or hyperglycemia. 327 
• Hospitals need to develop specific guidelines for using CGMs and AID systems for their 328 
affiliated nursing homes and skilled nursing facilities. 329 
 330 
Initiation of Continuous Glucose Monitors in the hospital  331 
Chair: Guillermo E. Umpierrez, MD, CDE 332 
Emory University School of Medicine, Atlanta, Georgia, USA 333 
POTENTIAL OPPORTUNITIES 334 
COVID-19 335 
The current COVID-19 pandemic created the need for innovative approaches for glycemic 336 
monitoring in the hospital4. Coincidentally, two weeks before this meeting, the FDA stated that 337 
they would exercise enforcement discretion and they would not object to the use of CGMs in 338 
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the hospital during the crisis2,3. This policy was intended for the factory-calibrated CGMs 339 
manufactured by Abbott Diabetes Care and Dexcom. Subsequently, these two manufacturers 340 
provided CGM supplies to hospitals to help monitor glucose remotely. Immediately afterward, 341 
several institutions started the process of implementing CGM use and realized that there was a 342 
need for training, implementation, and resource utilization and not all hospitals have this 343 
expertise. The announcement also resulted in new reports on the use of CGMs in the hospital. 344 
During the panel discussion, there was a recognition that this “exceptional” situation did not 345 
indicate “label approval” for CGM use in the hospital by regulatory bodies. Collaborative efforts 346 
from Emory University and DTS have recently provided examples of practical implementation of 347 
CGMs and use of diabetes technology in the hospital through creation of a website that 348 
contains information about original articles, commentary, news, and protocols related to 349 
COVID-19 and diabetes47 (covidindiabetes.org). Small pilot studies have provided unconfirmed 350 
evidence of the feasibility of remote glucose monitoring during this global crisis40. 351 
ICU Patients 352 
There is strong evidence from large prospective and randomized studies indicating that optimal 353 
glucose management results in improved outcomes, reduced complications, and a decreased 354 
length of stay (LOS)48,49. In the ICU setting, therapy with intravenous insulin infusion allows 355 
clinicians to maintain narrow glycemic targets. The panelists reviewed studies using CGMs in 356 
the ICU in adult populations (Table 3) and pediatric populations (Table 4).   357 
In the ICU, bedside POC glucose using factory-calibrated BGMs (performed every 1-2 hours) has 358 
been recommended as the preferred method to assess glycemic management and to guide 359 
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hyperglycemia treatment with intravenous insulin infusion. POC BG testing has drawbacks. This 360 
testing method is labor-intensive. Also, POC testing does not provide: 1) a full 24-hour glycemic 361 
profile, 2) predictions of hypoglycemic events, or 3) alarms for asymptomatic hypo- or 362 
hyperglycemia. Although the use of POC glucose testing, compared to central laboratory 363 
glucose testing, is approximately as convenient and generates faster results, another drawback 364 
is that it costs more. Estimated mean total costs (including equipment, supplies and labor) can 365 
be up to $5.13 per POC test in a high-test volume nursing unit, and up to $16.49 per POC test in 366 
a low-test volume nursing unit, compared to $3.78 for central laboratory glucose testing89. 367 
Moreover, the accuracy of POC glucose meters is not optimal, with only six of eighteen glucose 368 
monitor systems (representing 90% of commercially available meters and intended for 369 
outpatient use) meeting regulatory accuracy requirements17 in a recent study. In 2018 the FDA 370 
cleared the first POC glucose meter - the StatStrip Glucose (Nova Biomedical, Waltham, 371 
Massachusetts)- for all hospitalized patients, including critically ill patients, to test capillary, 372 
venous, and arterial blood specimens90. However, not all hospitals use this system to measure 373 
BG. While definitive validation of CGM accuracy in ICU patients is still forthcoming there 374 
remains a potential role for CGMs to measure glucose concentrations in this population. 46,91,92 375 
Non-ICU Patients 376 
Studies using older CGM technology that required regular recalibration have shown minimal 377 
differences in mean daily glucose, premeal, fasting, or 2-hour postprandial glucose levels 378 
between CGM and POC BG testing. In a pilot study, CGMs detected a higher number of 379 
hypoglycemic events compared to POC BG testing, particularly nocturnal or asymptomatic 380 
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hypoglycemia93. Few studies have been published on the use of newer factory calibrated CGMs 381 
in non-ICU settings.94  382 
A recent study of patients with T2DM admitted to general medicine and surgery wards and 383 
managed with basal-bolus insulin therapy, compared the FreeStyle Libre Pro (Abbott Diabetes 384 
Care, Alameda, California)95 to POC BG testing96. This CGM system is a variant of the FreeStyle 385 
Libre 14 day system, where glucose readings are available to the HCP but not to the patient. 386 
The FreeStyle Libre Pro CGM, compared to POC BG testing, showed a tendency towards lower 387 
mean glucose with an estimated mean glucose difference of 12.8 mg/dL (Confidence Interval, CI 388 
8.3-17.2). Accordingly, CGMs, compared to POC BG testing, were more sensitive at detecting 389 
hypoglycemic events. The overall Mean Absolute Relative Difference (MARD) was 14.8%. The 390 
percentage of glucose concentrations within the ±15% or 15mg/dL, ±20% or 20mg/dL, and 391 
±30% or 30mg/dL (where for CGM concentrations  ≤ 100 mg/dL, the units of the range were 392 
mg/dL and for CGM concentrations > 100 mg/dL, the units of the range were percent)  was 393 
62%, 76%, and 91%, respectively. A Clarke Error Grid analysis showed acceptable clinical 394 
accuracy with 98.0% of glucose concentrations falling into Zones A (75.1%, n=1,184) and B 395 
(23.7%, n=374).96 Panelists reviewed CGM studies in the non-ICU in adult populations (Table 5). 396 
Evidence suggests that initiating the use of CGMs in the non-ICU settings provides better 397 
glycemic monitoring, compared to standard 3-4 times daily POC BG testing, with improved 398 
detection and potential prevention of hypo- and hyperglycemic events. Most of these events, 399 
particularly nocturnal and asymptomatic hypoglycemia, might otherwise be missed. Ongoing 400 
hospital CGM studies listed on ClinicalTrials.gov97 may provide some guidance (Table 6).  401 
Glucose Telemetry  402 
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The hospital should possess the physical infrastructure to download the patient’s CGM data for 403 
the retrospective review of patterns in glycemia. CGM data can be automatically delivered to 404 
the nursing station by way of automatic downloading into a monitor at the nursing station. A 405 
recently published manuscript evaluated whether such a system for presenting CGM data, 406 
called the “Glucose Telemetry System”, can decrease hypoglycemia in the general wards/non-407 
ICU setting43. This report is the first interventional randomized controlled trial (RCT) study of 408 
CGM technology to improve outcomes in the non-ICU setting. The study included patients with 409 
T2DM, who were at high risk for hypoglycemia. Participants were randomized to either the 410 
“Glucose Telemetry System” (intervention group) or to POC BG testing (control group). For 411 
patients in the “Glucose Telemetry System”, nurses were instructed to proceed with 412 
hypoglycemia prevention actions if the low glucose alerts were activated (for a setting of BG < 413 
85 mg/dL). Participants in the control group were placed on “blinded” CGMs which were only 414 
used to collect glucometric data. Overall, the subjects in the “Glucose Telemetry System” 415 
experienced fewer events of hypoglycemia (BG < 70 mg/dL) and clinically significant 416 
hypoglycemia (BG < 54 mg/dL) compared to the POC BG group. The outcomes of the 417 
intervention versus control groups for these two levels of hypoglycemia were, respectively, 418 
0.67 versus 1.69 events/ patient, p =0.024 (BG < 70 mg/dL) and 0.08 versus 0.75 events/patient, 419 
p =0.003 (BG < 54 mg/dL). There was a reduction in percentage of time in hypoglycemic range 420 
(BG < 70 mg/dL and < 54 mg/dL) in the glucose telemetry system group compared to POC group 421 
(0.40% versus 1.88%, p =0.002 and 0.05% versus 0.82%, p =0.017). 422 
POTENTIAL BARRIERS 423 
Minimally Invasive CGMs  424 
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As discussed in previous consensus reports1,106 during the past 20 years, many studies have 425 
been published on the initiation of subcutaneous CGMs in critically ill patients (Table 3 and 4). 426 
However, most of those studies were intended to focus only on accuracy data and not clinical 427 
outcomes. In addition, it is difficult to reach conclusions from these reports because of different 428 
study designs and small sample sizes. A recent systematic review by van Steen et al. analyzed 429 
32 studies that assessed the accuracy of CGMs in the ICU. These authors reported moderate to 430 
good accuracy especially with intravascular devices107. The authors included only five RCTs for 431 
efficacy assessment and recognized methodological limitations 107. Panelists noted that there is 432 
currently insufficient data to provide definitive recommendations on improved outcomes based 433 
on reports in the medical literature.  434 
It is unclear whether CGMs will be able to fully replace POC BG testing and be approved as non-435 
adjunctive use for treatment decisions in acute care. Panelists had concerns with the accuracy 436 
of subcutaneous CGM values for the first hours after insertion to make treatment decisions or 437 
even during the first 1-2 days of use. Panelists also had concerns with the unintentional added 438 
burden on nursing when: 1) a CGM has overreported low glucoses values and these false low 439 
values have required POC confirmation, 2) new CGM technology must be learned during a 440 
crisis, and 3) time is needed for troubleshooting. In addition, skin-related issues have been 441 
mentioned in 19% of articles about recent CGMs.108–110   442 
Invasive CGMs  443 
Although these systems were not the focus of the guideline, the panelists briefly considered the 444 
role of invasive CGMs. They noted that few intravascular invasive sensors are cleared for ICU 445 
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patients. Also, compared to subcutaneous CGM sensors, intravascular sensors tend to have 446 
three main disadvantages. First, these systems are invasive and some are associated with 447 
vascular complications, such as thrombosis, catheter occlusion, biofilm formation, or 448 
intravascular catheter-related infections111. Second, they impose a higher implementation 449 
resource and care burden to patients and the ICU system. Third, they are not intended for non-450 
ICU settings. Therefore, intravascular CGMs, compared to subcutaneous CGMs, are less 451 
attractive options. 452 
Recommendations for Initiation of Continuous Glucose Monitors in the hospital  453 
Clinical Practice 454 
Strong Recommendation 455 
• HCPs should consider prescribing CGMs to reduce the need for frequent nurse contact 456 
for POC glucose testing and the use of PPE for patients on isolation with highly 457 
contagious infectious diseases (e.g. COVID-19). 458 
Mild Recommendation 459 
• HCPs should avoid initiating CGMs in patients with severe hypoglycemia or 460 
hyperglycemia (i.e. BG < 40 mg/dL or >500 mg/dL) or during periods of rapid glucose 461 
fluctuations. 462 
Research  463 
Strong Recommendations  464 
• Researchers need to provide data to support initiation of CGMs for improving patient-465 
centered outcomes. 466 
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• Researchers need to provide data on hospital outcomes when initiating CGMs in the 467 
hospital, including improved glycemic outcomes, detection and/or reduction of 468 
hypoglycemia and hyperglycemia, reduction of ICU LOS, and cost-effectiveness. 469 
• Researchers need to conduct studies on long term benefits for initiating CGMs in the 470 
hospital after discharging patients with newly diagnosed diabetes or recurrence of 471 
diabetic ketoacidosis (DKA) or other complications of diabetes. 472 
• Manufacturers need to develop educational tools for patients, hospital staff, and HCPs. 473 
Hospital Policies 474 
Strong Recommendations 475 
• Hospitals need to develop plans, including process maps, protocols, staff educational 476 
resources, and order sets for prescribing CGM use during hospitalizations prior to 477 
implementing a CGM. 478 
• Hospitals need to provide educational tools for patients, nurses, house staff, and 479 
attending physicians when a patient in the hospital starts on a CGM.  480 
 481 
Continuation of Automated Insulin Dosing Systems in the hospital 482 
Chair: Ananda Basu, MD, FRCP 483 
University of Virginia School of Medicine, Charlottesville, Virginia, USA 484 
POTENTIAL OPPORTUNITIES 485 
Improved Glycemic Outcomes  486 
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Evidence about the potential glycemic benefits of continuing AID systems from the outpatient 487 
into the inpatient setting is limited, and currently it is possible only to extrapolate data from 488 
studies of AID systems initiated during a hospital stay. Several such studies of initiating AID 489 
systems in the hospital have been performed in medical or surgical patients as well as in 490 
patients on hemodialysis or women in the peripartum/postpartum period112–119. In the largest 491 
of these studies112, Bally et al. reported that initiation of AID system technology in the hospital 492 
for patients receiving noncritical care achieved a higher percentage of TIR when compared to 493 
standard hospital management. The times in range were, respectively, 65.8 (±Standard 494 
Deviation 16.8)% vs 41.5(±16.9)%, with a difference of 24.3 (±2.9)% [95%CI 18.6 to 30.0; 495 
P<0.001). Mean glucose levels were lower in the AID system arm compared to the group 496 
treated with conventional subcutaneous insulin delivery (with the differences being 154 (± 29) 497 
mg/dL vs 188 (± 43 mg/dL), p <0.001) and there was no significant difference in time spent in 498 
hypoglycemia <54 mg/dL or < 70 mg/dL. AID systems have also been found to improve TIR in 499 
women in the peripartum/postpartum period113 and patients on hemodialysis114. AID system 500 
management has reduced surgical site infections resulting in shorter postoperative 501 
hospitalizations115. In a single center observational study that was performed in an ICU setting, 502 
use of AID system management compared to standard sliding scale insulin therapy led to a 503 
decreased frequency of blood sampling, reduced time required for achieving glycemic targets, 504 
and a decreased nursing workload per admission  of diabetes management from 68 (± 25) 505 
minutes (AID system) to 33 (± 21) minutes (sliding scale) (p < 0.001).116 In a randomized, 506 
parallel-group trial, inpatients with T2DM in the United Kingdom received fully closed loop 507 
insulin delivery without meal-time boluses which was found to be safe and effective117. In a 508 
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two-center open-label, randomized controlled trial of fully automated insulin dosing in the 509 
United Kingdom and Switzerland, this method was found to improve glycemic outcomes for 510 
inpatients receiving nutritional support118.  511 
Glycemic management in hospitalized patients aims to avoid both hypoglycemia and 512 
hyperglycemia. Since inpatients with diabetes are often in a compromised state of health and at 513 
risk for hypoglycemia because of interrupted nutrition, inadvertent insulin overdosages 514 
associated with intensive insulin therapy, or unexpected improvements in insulin sensitivity, 515 
hypoglycemia can be a serious problem for these patients. Special AID systems that can deliver 516 
both insulin and glucose have been created exclusively for inpatient use. A clinical study in 517 
Japan compared two such systems (differing in size and weight, but not algorithms) 518 
manufactured by Nikkiso Co., Ltd., and used for perioperative glycemic management. The 519 
newer (STG-55) and older (STG-22) AID system models120 both achieved similar glycemic control 520 
without hypoglycemia, leading the investigators to conclude that the newer (as well as smaller 521 
and lighter) system could potentially be used in routine practice for perioperative glycemic 522 
management119. A study in Denmark assessed an intravenous AID infusion system delivering 523 
both insulin and glucose based on a proprietary controller (Admetsys, Boston, 524 
Massachusetts)121.  525 
COVID-19 526 
With the COVID-19 pandemic, increased mortality has been associated with hyperglycemia 527 
both in patients diagnosed with diabetes prior to admission and those diagnosed with diabetes 528 
during their admission122. There is a paucity of high-quality data about optimal monitoring and 529 
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therapy and associated outcomes in these patients. The need for improved glycemic 530 
management for COVID-19 patients may accelerate the development of future novel glucose 531 
monitoring technologies in the hospital setting, including possibly closed loop control for 532 
intensively treated patients. During the pandemic, AID systems, if utilized, can also perhaps 533 
reduce the risk of nursing exposure, the time needed for donning and doffing for any needed 534 
BG monitoring, and the use of limited supplies of personal protective equipment.  535 
Patient Satisfaction 536 
Evidence about the potential benefits of using of AID systems in the inpatient setting is limited. 537 
Even for the more traditional non-AID CSII system, the available data is based on retrospective 538 
studies, because no randomized clinical trials have been performed123. One of these studies 539 
reported that outpatients on CSII systems, who had reasonable control (mean hemoglobin A1c 540 
7.5%)124,125, were sufficiently confident to continue self-managing their diabetes and use their 541 
own CSII systems during a hospitalization. Many of these CSII system users reported higher 542 
patient satisfaction (86%) when they were allowed to continue wearing their CSII system during 543 
their inpatient stay126. Similar outcomes are likely to be found with the use of AID systems. 544 
Asking hospitalized patients with diabetes to remove their AID system could result in decreased 545 
patient satisfaction, especially if their diabetes care is managed by healthcare professionals, 546 
who have limited experience with inpatient and outpatient diabetes management. 547 
Furthermore, a patient who must surrender their AID system upon hospitalization might 548 
express dissatisfaction with nocturnal POC BG testing.   549 
POTENTIAL BARRIERS 550 
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Patient-Related Factors 551 
Although AID systems can be beneficial, five types of factors may preclude their use in the 552 
inpatient setting.123,124,127 They can be divided into the following categories: 1) patient-related, 553 
2) hospital-related, 3) device-related, 4) medication-related, and 5) surgical procedure-related. 554 
Examples of patient-related conditions in which AID systems should not be used are physical or 555 
psychiatric conditions which can make patients incapable of self-managing an AID system in the 556 
hospital. Contraindications to CSII system and AID system therapy in the hospital are presented 557 
in Table 7. Patients should be able to self-manage their AID systems and provide their pump 558 
settings to the treating HCPs in case the AID system may need to be discontinued. Patients with 559 
severe metabolic decompensations, such as DKA123, acute kidney injury, post-transplant T1DM 560 
patients in acute rejection, or those with severe sepsis and hypovolemia, which may lead to 561 
tissue hypo-perfusion, should also probably not use AID systems in the hospital. Skin infections 562 
may represent another contraindication, especially if they are extensive, because they may 563 
preclude CGM or pump placement. However, it is still unclear whether the above conditions 564 
can significantly affect the function of AID systems and more research is needed in this area.  565 
Hospital-Related Factors  566 
Examples of hospital related factors are situations where there are no policies in place that can 567 
safeguard the use of AID systems in the inpatient setting and delineate the roles of the patients, 568 
nurses, and HCPs124,127. Because only limited information is currently available about the use of 569 
AID systems in the hospital, further research is needed in order to provide evidence-based 570 
recommendations127. Another potential obstacle to the use of AID systems in the inpatient 571 
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setting is the lack of nurses and HCPs who are adequately trained in the use and interpretation 572 
of data from the AID systems. However, it is unclear whether AID systems do or do not lead to 573 
increased workload for nursing and/or HCPs. 574 
Device-Related Factors  575 
Limitations related to device use include clinical scenarios where AID systems cannot be used 576 
because of a device malfunction or insufficient medical supplies, either for the continuous 577 
insulin infusion set or for the CGM components. A CGM can become compressed during a 578 
prolonged period of a prone position, such as with sleep or prone ventilation, and produce a 579 
false low reading, which could also pose another limitation to their use 128,129. For AID systems 580 
that require the patient to select a meal-time bolus dose recommended by a bolus calculator, 581 
unexpected failure to reach postprandial glycemic targets could be due to manufacturer-582 
specific pump settings resulting in a different dose recommendation by each pump brand.130 583 
Medication-Related and Meal-Related Factors 584 
Medications, such as glucocorticoids, which can cause severe insulin resistance and 585 
uncontrolled hyperglycemia, may present a challenge for some AID systems, but others may 586 
adapt well to changes in insulin resistance during periods of illness131. Other challenging 587 
scenarios are nutritional interruptions, which are very common in a busy hospital 588 
environment131. Nutrition in the inpatient setting is more complicated than in the ambulatory 589 
environment. Patients may have nausea, vomiting, or other conditions that can affect nutrient 590 
absorption and therefore create irregular patterns in the glucose values. Insulin is not always 591 
administered at the right time before the meal is delivered. Meals can be interrupted or 592 
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delayed and tube feedings and parenteral nutrition (either peripheral or total) can be suddenly 593 
discontinued. Although the above scenarios are not absolute treatment-related 594 
contraindications, they represent challenging situations for AID system use in the hospital. HCPs 595 
should also be aware about the potential interactions of certain medications with subcutaneous 596 
CGMs (Table 2). Additional studies are required to determine the effects, if any, of multiple 597 
doses and combinations of potentially interfering medications on CGM accuracy.    598 
Surgical Procedure-Related Factors 599 
Surgical procedures can create additional barriers to the use of AID systems in the inpatient 600 
setting123,125,132. Surgical procedures can be broadly divided into two different categories, 601 
elective or urgent. Elective surgeries can provide sufficient time for pre-admission preparation. 602 
The endocrinology clinician or diabetes team would coordinate care between the different 603 
subspecialties that are involved such as the anesthesiology, surgical and inpatient diabetes 604 
teams (if they are available and different from the primary endocrinologist) about the 605 
upcoming surgical procedure. The panel recognized that many hospitals do not have a diabetes 606 
team or inpatient diabetes educator. Patients need to be instructed to insert the sensor and the 607 
insulin cannula away from the operative field and change the sites one day prior to the surgery. 608 
Urgent surgeries do not allow for such planning. In the immediate preoperative period, for 609 
either elective or urgent surgical procedures, the inpatient diabetes team should be notified, if 610 
this has not been done earlier. Consent must be obtained from the patient about the use of an 611 
AID system during surgery. Temporary higher glycemic targets may be needed to allow slightly 612 
higher glucose values during surgery to decrease the risk of hypoglycemia in an unconscious 613 
patient. Ideally, the anesthesiology team would need to be familiar with the use of an AID 614 
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system during the intraoperative period so the team can control or suspend the pump if 615 
necessary because the unconscious patient will not be able to adjust the settings themselves. 616 
However, it is unclear whether it would be realistic to expect an anesthesiologist to learn the 617 
operation of an AID system and there is no data about anesthesiologists operating AID systems 618 
during surgery. The basal insulin delivery rate is determined by an AID system controller. If the 619 
team members are able to manage the AID system, then they should also have easy access and 620 
proximity to the AID system intraoperatively. The use of an AID system during surgery is not 621 
recommended if the insulin requirements are expected to fluctuate significantly 622 
intraoperatively. In that case intravenous insulin delivery with insulin dosing software instead of 623 
subcutaneous insulin delivery would be more appropriate with either an intravenous or 624 
subcutaneous glucose sensor. AID systems can be continued during the operation if there are 625 
no concerns regarding device malfunction. However, there is no good data available on the 626 
safety or maximum safe duration of closed loop control during anesthesia. Even with control by 627 
an AID system, BG concentrations should be monitored intraoperatively.   628 
 629 
Recommendations for Continuation of Automated Insulin Dosing Systems in the hospital 630 
Clinical Practice 631 
Strong Recommendations 632 
• HCPs should prescribe AID systems only for appropriate candidates, who will need to 633 
have adequate knowledge and skills for using AID systems 634 
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• HCPs should reassess a decision periodically to transition use of outpatient AID systems 635 
into the hospital in order to ensure that AID system continue to represent the best 636 
treatment option for each patient 637 
• HCPs should prepare an alternative plan for diabetes management in case it becomes 638 
inappropriate for a patient to continue using an AID system in the hospital 639 
• HCPs should discontinue AID systems in critically ill hospitalized patients (such as those 640 
with hypovolemia or sepsis) 641 
• HCPs should recognize glycemic patterns due to CGM compression, which can cause 642 
false low readings  643 
Mild Recommendation 644 
• HCPs should avoid initiating an AID system during a hospitalization 645 
Research 646 
Strong Recommendations 647 
• Researchers need to conduct studies about whether continuing AID systems in the 648 
hospital is beneficial to improve glycemic management or clinical outcomes 649 
• Researchers need to provide data on hospital outcomes when using AID systems in the 650 
hospital, including improved glycemic outcomes, detection and/or reduction of 651 
hypoglycemia, reduction of ICU LOS, and cost-effectiveness 652 
• Manufacturers need to research whether all types of CGMs and AID systems can be 653 
used during radiological/imaging studies or diathermy 654 
Hospital Policies 655 
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Strong Recommendations 656 
• Hospitals need to develop institution-specific protocols and order sets for the proper 657 
use of AID systems during a hospitalization 658 
• Hospitals need to require that patients using AID systems bring with them sufficient 659 
supplies for these devices during a hospitalization 660 
• Hospitals need to develop protocols for using AID systems during elective procedures 661 
and surgeries 662 
Recommendation Not Reaching Consensus 663 
• HCPs should switch AID systems from “auto” mode to “manual” mode when a patient is 664 
admitted to the hospital wearing an AID system 665 
 666 
Logistics and hands-on care of hospitalized patients using Continuous Glucose Monitors and 667 
Automated Insulin Dosing Systems 668 
Chair: Suzanne Lohnes, MA, RN, CDCES, CPT 669 
University of California San Diego Medical Center, La Jolla, California, USA 670 
POTENTIAL OPPORTUNITIES 671 
Expectations for Patients and Hospital Staff and Practical Considerations for Use of CGMs and 672 
AID systems in the Acute Care Setting 673 
Continuation of CGM use can be a helpful adjunct to management in the acute care setting and 674 
can increase patient satisfaction. However, because CGMs are not currently cleared by FDA for 675 
the inpatient environment, a policy addressing practical considerations for use of CGMs and AID 676 
systems in hospitalized patients is needed.  677 
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 678 
POTENTIAL BARRIERS 679 
Necessary Hospital Responsibilities  680 
It is important that key tasks, roles, and responsibilities, related to work system domains 681 
(technology/data, tasks, personnel, structure/organization, and environment) are addressed for 682 
safe and effective implementation.133 Below are listed potential responsibilities delineated by 683 
team members. It is helpful for diabetes team members to be interchangeable (e.g. 684 
subspecialty consultant with pharmacist or nurse with patient care technician). Furthermore, it 685 
is appropriate to predefine tasks, person assignments, policies, procedures, and a clear 686 
organizational structure (e.g. determination of committee reporting) around monitoring and 687 
interpretation of data, to facilitate use of CGMs and AID systems.  688 
Necessary Patient Responsibilities  689 
Patients who wish to continue use of CGMs or AID systems in the acute care setting should read 690 
a detailed set of information and should review and sign a patient agreement about hospital 691 
policy. The panel developed a sample patient agreement for the use of CGMs or AID systems in 692 
the hospital presented in Figure 1. This agreement is meant to be an example for a 693 
subcutaneous non-implanted sensor. Each institution must develop their own agreement and 694 
they should consider manufacturer labeling.   695 
CGMs may be used for guidance about the direction and magnitude of changes in glucose 696 
concentrations. The patient should notify hospital staff if they are observing glucose excursions 697 
out of range or if they experience symptoms of hypoglycemia. The patient should bring all 698 
supplies (infusion sets, sensors, receiver, etc.) needed for continuation of home use for the 699 
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duration of a hospitalization and be responsible for maintenance of their device and changing 700 
sites as directed during a hospitalization. Device supplies may be stored per hospital policy and 701 
will be returned to the patient upon discharge.  702 
Necessary HCP Responsibilities 703 
Inpatient caregivers must: 1) confirm that it is appropriate for a patient to continue using a 704 
CGM or an AID system, 2) discuss hospital policy with the patient, and 3) review an agreement 705 
with the patient. After the patient agreement is signed, the HCP should place an order for 706 
inpatient use of a CGM or an AID system. A patient’s ability to safely continue use of a CGM or 707 
an AID system (which may change during the hospitalization) must be regularly assessed by 708 
nursing staff and HCPs.134 Daily documentation per institutional policy will be needed 709 
throughout the hospitalization. If there is concern for patient’s ability to use a CGM or an AID 710 
system, then the caregiver will recommend an alternative treatment plan. 711 
Necessary Nursing Responsibilities  712 
In collaboration with other inpatient HCPs, it is important for nursing to assess the patient’s 713 
suitability for using a CGM or an AID system and review hospital policies with the patient. It is 714 
also important for nursing to assess the insertion site and document site changes in the EHR.  715 
Treatment decisions based on CGM data linked to insulin dosing software might lead to 716 
unwanted outcomes unless the safety and efficacy of the system in the acute care setting can 717 
be clearly established. For patients using AID systems in the hospital who are going to be 718 
transitioned to and/or discharged with subcutaneous multiple dose insulin therapy, if the 719 
insulin dosing information (from “auto” mode) is not available in the EHR, then an estimate of 720 
insulin requirements might be inaccurate and could lead to dysglycemia following discharge.  721 
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Standard approaches to documentation are also needed. The panel recognized a spectrum of 722 
practice for nursing documentation and institutional requirements. Nursing should document 723 
all AID system device settings, including any insulin boluses in “manual” mode, in the inpatient 724 
progress notes and/or in the patient’s bedside log which is scanned into the EHR. Additionally, 725 
the frequency that this information is documented (i.e. every shift vs. daily) may vary based on 726 
individual hospital resources and policies.  727 
Specialty Consultation  728 
When using CGMs or AID systems in the acute care setting, specialty consultation, if available, is 729 
required and the request for consultation should be documented. While some institutions have 730 
inpatient diabetes support available for in-person consultation and ongoing management, the 731 
panel recognizes there are circumstances in which inpatient diabetes expertise may not be 732 
readily available. The panel suggested consideration for telemedicine consultation with a 733 
diabetes specialist if necessary. It is useful to document the patient’s ability to use the 734 
technology to assist with glucose management. 735 
Recommendations for Logistics and hands-on care of hospitalized patients using Continuous 736 
Glucose Monitors and Automated Insulin Dosing Systems 737 
Clinical Practice 738 
Strong Recommendations  739 
• HCPs should inquire about and document the medication and supplement history of 740 
patients who use CGMs to determine whether there are any agents that can interfere 741 
with glucose measurements 742 
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• HCPs should ensure that off-label use of CGMs and AID systems is consistent with 743 
medical practice and appropriate precautions have been taken to protect patients 744 
• Nursing should document hands-on training of CGM use and AID system therapy 745 
through a technology certification program 746 
• Nursing should confirm that the patient is appropriate to continue using a CGM or an 747 
AID system and also review the agreement and hospital policy with the patient 748 
• Nursing should inspect the insertion site every shift with attention to skin integrity and 749 
signs of erythema or infection, and should document site changes 750 
• Nursing should know device basics, institutional policies, HCPs roles, and whom to 751 
contact if questions arise 752 
• Nursing should administer a patient competency assessment or survey to assess patient 753 
ability to safely assist with managing a CGM or an AID system 754 
• Nursing should set expectations and clarify that there will be a need to continue 755 
checking POC capillary glucose even when using a CGM. 756 
• Nursing should measure POC BG concentrations to confirm or supplement CGM 757 
readings (usually a minimum of 4 times daily: before each of three meals and at bedtime 758 
if patients are eating, or every 6 hours if patients are fasting) as well as at patient 759 
request; however, the CGM glucose, trend arrows, and rate of change may be used to 760 
help determine if and when a BG test is required. 761 
Research 762 
Strong Recommendations 763 
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• Researchers need to conduct further studies on the best logistics and hands on care for 764 
patients using CGMs and AID systems to achieve the best outcomes 765 
• Manufacturers need to research interoperable components for AID systems that are 766 
compatible with hospital EHRs 767 
Hospital Policies 768 
Strong Recommendations  769 
• Hospitals need to provide interpreter services to translate CGM and AID system 770 
agreements 771 
• Hospitals need to state in their policy and patient agreement documents that treatment 772 
decisions will be based on hospital-calibrated BGM readings (or laboratory readings) and 773 
not on CGM readings, barring a need to isolate a patient with a severe and highly 774 
contagious infection 775 
• Hospitals need to maintain their CGM and AID system policy and patient agreement 776 
documents in easily accessible electronic files stored in the EHR order set for CGMs and 777 
AID systems 778 
• Hospitals need to develop policies for when to discontinue or temporarily suspend the 779 
use of CGMs and AID systems 780 
• Hospitals need to survey their HCPs, nursing, and patients to improve outcomes and 781 
satisfaction 782 
 783 
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Data management of Continuous Glucose Monitors and Automated Insulin Dosing Systems in 784 
the hospital 785 
Chair: James H. Nichols, PhD, DABCC, FAACC 786 
Vanderbilt University Medical Center, Nashville, TN, USA 787 
POTENTIAL OPPORTUNITIES 788 
Policies and Procedures 789 
As previously noted, there is a distinction between CGM glucose values and laboratory glucose 790 
values, and CGM data is currently not part of the laboratory information system. Rather, CGM 791 
data is analogous to ICU vital sign monitoring data rather than lab values like serum potassium 792 
and sodium. Because of this distinction, it is important to consider where in the medical records 793 
this data should reside and how they should be displayed, such as in reports, tables, or graphs. 794 
Given this known difference between CGM glucose values and lab glucose values,135 criteria 795 
should also be developed on when to check or cross-reference CGM values with a POC or 796 
laboratory glucose test. A related question is whether or not clinical decisions should be made 797 
on the basis of CGM data, or whether clinicians should always obtain a laboratory or POC 798 
glucose test for treatment decision making. Finally, criteria should be established as to whether 799 
a minimum number of laboratory or POC BG tests must be performed while patients are using 800 
CGMs or AID systems in the hospital. Manufacturers of some CGMs have recommended a 801 
calibration frequency, but those recommendations are intended for outpatient use, and might 802 
not be adequate for inpatient use. 803 
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As part of the standardization of summary metrics, we should also develop clear criteria for 804 
values or trends that require a clinical intervention. The panel discussed creating a framework 805 
for clinical action based on CGM data. This includes understanding what data and trends are 806 
actionable, as well as what the appropriate clinical interventions might be. Critical values are 807 
considered to be imminently life-threatening test results that require immediate contact by the 808 
ordering HCPs. CGMs can trend the rise and fall of glucose concentrations, and can predict critical 809 
hypo- or hyperglycemia. Data management systems can be set to alarm when CGM glucose 810 
trends reach or cross certain critical values. These alarms should lead to clinician and patient 811 
notification so that appropriate actions may be taken in a timely fashion.  812 
The panel noted that data and security are major concerns in Germany and the rest of Europe. In 813 
Europe, every manufacturer uses a different data scheme and interface to download their data, 814 
which can be confusing.   815 
Information Technology (IT) Infrastructure 816 
The Health Insurance Portability and Accountability Act of 1996 (HIPAA) protects health 817 
information, promotes transparency, trust, and patient welfare in medical practice. Since CGMs 818 
and AID systems collect protected health information (PHI), when they are used by institutions 819 
and clinicians to make medical decisions, institutions have a responsibility to treat it like all 820 
other PHI, meaning they must ensure the integrity, security, and appropriate availability of that 821 
data. Documenting CGM results and data in the EHR designates it as part of the medical record, 822 
and it becomes subject to HIPAA. The IT department is needed to assist with licenses to 823 
download the data, and install the software into each hospital system. 824 
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Healthcare facilities should adopt the Unique Device Identifier (UDI) system to track devices in 825 
the EHR. In 2013, the FDA issued guidelines for the implementation of a global UDI  system to 826 
adequately identify and track medical devices across their lifecycle ,from distribution to patient 827 
use136. The UDI final rule established a timeline for all qualifying medical devices in the US to be 828 
compliant with UDI labeling by 2022 137. Diabetes technologies like BGMs, CGMs, CSII systems, 829 
and AID systems are all required to bear a UDI. Institutions should rapidly move toward UDI 830 
adoption and integration into the EHR, and ensure that CGM and AID system data is associated 831 
with the correct UDI for safety and quality assurance. 832 
Data 833 
Panelists recognized that there is limited evidence on how CGM data is integrated into EHRs at 834 
this time. With the near-universal adoption of EHRs among inpatient facilities in the United 835 
States 138, integrating device data into the EHR is important for quality and consistency. Several 836 
groups have explored the integration of these data into the EHR 139–141, but many questions still 837 
remain regarding best practices for the acquisition, storage, display, and use of that data. 838 
Distinctions should be made when recording CGM data in the EHR, since CGM data differs from 839 
laboratory glucose results. CGMs measure glucose within interstitial fluid, while laboratory 840 
instruments measure glucose in plasma, serum, or whole blood. This means that CGM data may 841 
not agree with laboratory glucose measurements collected at the same time.135 While individual 842 
CGM data points may be less precise than lab instrumentation generated values, a major 843 
advantage offered by CGMs is the presentation of multiple data points over time. These create 844 
an opportunity to evaluate glucose patterns as well as trends in the rate of change, percent of 845 
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time spent hypo- or hyperglycemic or within target range, and estimate stability/instability of the 846 
glucose concentration over time. These summary patterns may be more valuable than individual 847 
data points and provide a synthesis of the patient’s overall glycemic status. 848 
Data Patterns 849 
As EHR integrations of CGM data become more common, HCPs with a wider variety of 850 
backgrounds in training and experience with CGM data interpretation will have access to this 851 
data. Some might be less familiar with its use and interpretation. It is important that 852 
standardized, clear, and interpretable summary metrics be established in order to facilitate the 853 
clinical use of CGM data in the hospital setting. 854 
When considering how to integrate device data, the first decision is how to source data. There 855 
are two main options: 1) obtaining the data directly on a platform provided by the manufacturer 856 
(e.g. Abbott, Dexcom, or Medtronic) and 2) obtaining the data from a third-party aggregator, e.g. 857 
Tidepool (Tidepool, Palo Alto, California) or Glooko (Glooko, Inc., Mountain View, California). 858 
Each of these approaches has advantages and disadvantages, as well as associated costs and 859 
technical requirements. It may be reasonable to use a hybrid approach, connecting directly with 860 
a few manufacturers that have significant market share, and then using an aggregator to capture 861 
other devices. 862 
The next decision is what data to extract. There are several options for extracting, storing and 863 
displaying CGM data, and at varying levels of complexity (Table 8). Static reports (view only 864 
documents, typically PDFs) are the simplest, and some CGM manufacturers have already 865 
developed mechanisms to bring the CGM reports found on their provider platforms into the EHR. 866 
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Structured summary data are predefined and standardized, and can be added to existing data 867 
tables in the EHR for charting, trending, etc. Structured continuous data refers to the hundreds 868 
of daily individual blood glucose measurements, and is the most complex to manage, but 869 
potentially offers the most flexibility and control. 870 
Data storage and display will be dictated by the type of data extracted from the device. Reports 871 
and structured summary data can be stored in native EHR data tables, but continuous glucose 872 
readings would likely overwhelm those tables, and would best be stored in a separate 873 
environment. In terms of displaying the data, this can be accomplished in a variety of ways 874 
described in Table 8. 875 
A consensus list of core data elements should be developed and standardized across all models 876 
and manufacturers. Data standards and ontologies are critical for ensuring interoperability across 877 
information systems142. A core set of data elements and definitions developed and applied by the 878 
entire CGM industry would facilitate storage and use of CGM data. Finally, core data elements 879 
would ideally be submitted to the appropriate governing bodies for inclusion in existing 880 
healthcare ontologies and common data models, such as Systematized Nomenclature of 881 
Medicine—Clinical Term (SNOMED-CT), Logical Observation Identifiers Names and Codes 882 
(LOINC), and Observational Medical Outcomes Partnership (OMOP). 883 
Patient-reported outcomes (PROs) are any reports of the status of a patient's health condition 884 
that come directly from the patient, without interpretation of the patient's response by a clinician 885 
or anyone else.143 PROs can be leveraged for research, clinical care, and quality improvement. 886 
While several groups are actively working on the development of PROs in diabetes, there is still 887 
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significant work to be done144. The development, dissemination, and implementation of diabetes 888 
technology-specific PROs will enable a more holistic approach to patient care and research. 889 
Atypical Scenarios 890 
Guidelines should address the use of CGMs and AID systems for diagnoses other than diabetes, 891 
where glucose monitoring is valuable. In pediatrics, several clinical situations require close 892 
monitoring of BG concentrations and tight glycemic control, such as the titration of glucose 893 
infusion rates in premature infants on total parenteral nutrition. Early detection of hypoglycemia 894 
in infants with inborn errors of metabolism (e.g., fatty acid oxidation disorders, ketotic 895 
hypoglycemic disorders, and disorders of gluconeogenesis) could be another critical use for CGMs 896 
in the hospital setting. In these diseases, infants are often allowed to become hypoglycemic as a 897 
challenge in order to draw critical diagnostic labs. CGM measurements could make that process 898 
less stressful for parents and HCPs and safer for patients. 899 
Economic Analysis 900 
Panelists had concerns with the costs of some CGMs and AID systems being a limiting factor (i.e., 901 
batteries, sensors, transmitters, and/or a monitor or smartphone), but found that some CGMs 902 
are affordable. Panelists considered questions about the reimbursement for these devices. Who 903 
is responsible for covering their costs and consumable components? What if the patient has a 904 
device from one manufacturer, but the hospital only stocks supplies from a different 905 
manufacturer? Panelists also discussed the economic implications of CGM and AID system use in 906 
hospitalized patients. Inpatient hypo- and hyperglycemia, which might prove to be reduced with 907 
structured CGM or AID system programs, have been associated with increased LOS, 908 
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readmissions, and costs48,145. In patients undergoing cardiac surgery, studies suggested potential 909 
cost saving with intensive glycemic management (targeting 100 -140 mg/dL)146. Finally, panelists 910 
acknowledged the need for well-powered studies comparing the use of CGMs vs POC BGMs on 911 
hospitalization costs. 147 912 
POTENTIAL BARRIERS 913 
Regulatory Considerations 914 
The Clinical and Laboratory Improvement Amendment of 1988 (CLIA) sets a minimum quality 915 
standard for any laboratory test performed in the US for patient care or clinical decision making. 916 
Externally attached patient-dedicated monitoring devices like pulse oximetry capnography are 917 
not subject to CLIA148. CGMs and AID systems are also automatic monitoring devices that are 918 
wearable and continuously or intermittently detect glucose concentrations in interstitial fluid or 919 
tissue fluid. There is no sample collection and analysis in a separate instrument that can be 920 
calibrated or validated with a Quality Control sample. As such, a CGM is more of a monitoring 921 
device than a laboratory instrument, and should not be subject to CLIA.  922 
Although CGMs and AID systems should not be subject to CLIA, quality control is still an important 923 
consideration for inpatient CGM and AID system use. Previous consensus panels have stressed 924 
the need for clear safety and quality protocols to be in place1. There is known variation between 925 
sensors, both between brands and within brands. Also, calibration errors can lead to significant 926 
deviations in glucose values. Currently some hospitals using CGMs require a patient agreement, 927 
which outlines that the patient can still use their CGM, but hospital BGM testing is still 928 
mandatory. See Figure 1 for a sample agreement. In Germany, laboratory quality control 929 
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guidelines require twice daily internal testing and quarterly external testing for hospital lab 930 
meters149. This is a prerequisite for the use of data for diagnostic or therapeutic decisions. With 931 
CGMs, there is no sample and no control materials, so these procedures cannot be applied to 932 
CGMs, which is why some BG monitoring is still mandatory in the hospital. One possible path 933 
forward is for manufacturers to develop a mechanism to perform quality control procedures for 934 
CGMs. Otherwise, CGMs in the hospital may be limited to adjunctive use only. 935 
Off-label use of prescription drugs and devices is common in modern medical practice, and has 936 
been recognized as “an accepted and necessary corollary of the FDA’s mission to regulate in 937 
this area without directly interfering with the practice of medicine” by the United States 938 
Supreme Court 150. A manufacturer may not market unapproved uses of a medical device, but a 939 
physician may in their independent judgement decide to use a cleared device in an off-label 940 
manner. While off-label use is seen as accepted practice, it does not shield physicians from 941 
liability, and there is potential tort exposure. Whether a hospital would also be liable under 942 
those circumstances would probably depend on what sort of control it exerted over the 943 
physician.  If it is for an employed physician, then the hospital might be liable for the physician’s 944 
actions under a theory of respondeat superior, which is a doctrine that states that an employer 945 
is responsible for the acts of an employee.  If the physician is an independent 946 
contractor, then hospital liability for the physician’s actions would be more difficult to 947 
establish.  One way to evaluate the liability or legal risk of off-label use is to consider whether 948 
or not that action may expose the practitioner to a claim of negligence or malpractice. 949 
Negligence can be thought of as a breach in duty (for example, to a patient), or as the failure to 950 
act reasonably in light of foreseeable consequences.  951 
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 952 
Data privacy and security 953 
Another potential risk is around the data itself, and whether it is being stored and protected 954 
with the proper precautions for PHI. Overall, this should not be seen as an obstacle provided it 955 
is consistent with standard practice.  Tracking UDIs may also be an appropriate risk mitigation 956 
step that can address some safety and quality concerns. Software whose sole purpose is to 957 
store and summarize data may not be considered a medical device, but there are still privacy 958 
and cyber-security concerns with these products 151,152. Document retention policies are 959 
important in order to protect HCPs and hospitals from possible legal actions. In situations 960 
where the hospital is developing custom institutional (“home-brewed”) software, it is 961 
important to follow cybersecurity risk management standards and realize that not all insurance 962 
policies cover cyber security breaches related to custom developed software. Risk management 963 
teams should be in close communication with their insurance brokers to ensure appropriate 964 
coverage for that type of activity. 965 
Finally, it may be important to develop maturity models for diabetes technology. Maturity 966 
models are tools developed in the information technology field to provide guidance to 967 
organizations for assessing their current level of development in a particular topic, as well as a 968 
roadmap for systemic and structured improvement 153. Healthcare IT maturity models have been 969 
developed to cover a variety of topics, ranging from continuity of care and healthcare analytics, 970 
to telemedicine and mobile technology 154. Diabetes technology integration would greatly benefit 971 
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from a maturity model to help guide implementation at healthcare institutions in a systematic 972 
way. 973 
Recommendations for Data management of Continuous Glucose Monitors and Automated 974 
Insulin Dosing Systems in the hospital 975 
Clinical Practice 976 
Strong Recommendation 977 
• HCPs should develop a set of core data elements and definitions for CGM data for 978 
inclusion in common data models and the her 979 
Mild Recommendation 980 
• Nursing should contact an HCP immediately when CGM results cross critical value 981 
thresholds set by the institution 982 
Research 983 
Strong Recommendations 984 
• Researchers need to conduct further studies on the best data management practices of 985 
CGMs and AID systems 986 
• Researchers need to develop and validate robust glucose telemetry systems for both 987 
ICU and non-ICU populations 988 
• Researchers need to develop a diabetes technology maturity model that helps 989 
institutions understand the requirements to successfully integrate diabetes-related data 990 
and technology 991 
• Researchers need to develop, disseminate, and validate CGM- and AID system-specific 992 
PROs Measures to improve patient care 993 
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• Manufacturers need to research methods for quality control for CGMs and AID systems, 994 
which is critical as part of inpatient use of CGMs and AID systems 995 
• Manufacturers need to research optimally expanded device labeling in order to 996 
overcome clinical inertia and align practice with regulatory policy 997 
• Manufacturers need to research systems for integration of CGM data following initial 998 
upload into the cloud (e.g. the Eversense CGM) subsequently into the EHR 999 
• Manufacturers need to research secure communications systems for protecting data 1000 
from wireless wearables, telemedicine systems, and Bring-Your-Own-Device portable 1001 
computers used by HCPs (also known as “data in motion”) 1002 
Mild Recommendation 1003 
• Researchers need to develop computerized insulin decision support system that will 1004 
integrate with CGMs 1005 
Hospital Policies 1006 
Strong Recommendations 1007 
• Hospitals need to develop appropriate security protocols, dedicated data storage, 1008 
visualization tools, and adequate cyber insurance coverage (also known as"data at rest") 1009 
• Hospitals need to integrate AID system data into the EHR system for nursing and HCPs 1010 
to have easy access to this information 1011 
• Hospitals need to determine the number of laboratory or POC BG tests that must be 1012 
performed while patients are using CGMs or AID systems in the hospital. 1013 
• Hospitals need to adopt the UDI (Unique Device Identifier) system for healthcare 1014 
facilities to track devices in the EHR 1015 
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• Hospitals need to identify CGM data reports in the patient’s EHR to distinguish them 1016 
from laboratory glucose results 1017 
• Hospitals need to present clear criteria to clinicians to identify data that will require 1018 
intervention 1019 
• Hospitals need to implement CGM- and AID system-specific PROs to improve patient 1020 
care 1021 
• Hospitals need to develop a universal platform for their EHRs that can be used by all 1022 
CGMs to present core data elements, summary glucometrics, consistent formats, and 1023 
uniform interfaces across all CGM products 1024 
• Hospitals need to arrange for CGM results to be automatically uploaded into the EHR 1025 
• Hospitals need to manage CGM data with the same safety and security measures as all 1026 
other PHI 1027 
• Hospitals need to develop policies for CGM and AID system use with atypical scenarios 1028 
outside of diabetes, when glucose monitoring is valuable 1029 
 1030 
Conclusion 1031 
This consensus guideline for subcutaneous CGMs and AID systems was created to provide 1032 
recommendations to clinicians, researchers, and hospitals for promoting the safe and effective 1033 
use of CGMs and AID systems in the hospital environment. Through a consensus process, an 1034 
international expert panel voted on 78 recommendations. 77 of the recommendations were 1035 
classified as either strong or mild, and 1 failed to reach consensus (Table 9). The panel’s 1036 
recommendations are intended to support clinical practice, future research, and improved 1037 
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hospital policies, to facilitate the use of these tools. The success of this guideline will be the 1038 
impact to clinicians, researchers, manufacturers, and hospitals in the management of 1039 
hospitalized patients with diabetes.    1040 
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Tables and Figure 1554 
Table 1. The five topics discussed at the Continuous Glucose Monitors and Automated Insulin 1555 
Dosing Systems in the Hospital Panel 1556 
Topic 1: Continuation of home Continuous Glucose Monitors after hospitalization 
Topic 2: Initiation of Continuous Glucose Monitors in the hospital 
Topic 3: Continuation of Automated Insulin Dosing Systems in the hospital 
Topic 4: Logistics and hands-on care of hospitalized patients using Continuous Glucose 
Monitors and Automated Insulin Dosing Systems 
Topic 5: Data management of Continuous Glucose Monitors and Automated Insulin Dosing 
Systems in the hospital 
 
 1557 
Table 2. List of Currently Available Subcutaneous CGM Devices and their Interferences 1558 








Abbott Diabetes Care 
FreeStyle Libre 14 
day system 28 
Glucose Oxidase 





up 1 hours; 14 
days of sensor 
wear; Range 40-
500 mg/dL; No 
predictive alerts; 
Requires scanning 
at least every 8 
hrs 
 
Ascorbic Acid  
Salicylic Acid 
Abbott Diabetes Care 
FreeStyle Libre 229,30  





up 1 hours; 14 
Ascorbic Acid  
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days of sensor 
wear; Range 40-





and signal loss; 
Requires scanning 
at least every 8 
hrs 
 





Warm-up 2 hours; 
10 days of sensor 











GO  Requires 2-4 
calibrations/d; 
Warm-up 2 hours; 
7 days of sensor 
















Warm-up 24 hrs; 













Table 3. CGM Studies in the ICU in Adult Populations    1560 
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Gas Analyzer, YSI 
(YSI 2300 STAT 
Plus Glucose and 
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Yellow Springs, 





Glucoday A. Menarini 
Diagnostics 
Reliability Arterial  
Price, 
2008,54  




Accuracy Arterial by Blood 
























Capillary by POC 





STG 22 Nikkiso Co., Ltd., 
(Nikkiso Co., Ltd., 
Tokyo, Japan) 












and Venous by 
POC 



















Arterial by Blood 















Capillary by POC  
Brunner, 
2011,61  
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Capillary by POC 
Schuster, 
201467 
SICU (n: 24) Guardian Medtronic 
MiniMed 
Accuracy Capillary by POC 














Arterial by Blood 











Central Venous by 









Central Venous by 
Blood Gas 




























SICU, n: 14 Sentrino Medtronic 
MiniMed 










Arterial by Blood 





s, 201574  
MICU, n: 18 Soft Sensor Medtronic 
MiniMed 
Accuracy Capillary by POC 
Nohra, 
201675 


























Accuracy Arterial by Blood 
Gas Analyzer 
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 1561 
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Care and Maquet 
Getinge Group 
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Gas Analyzer and 
Capillary by POC 
Song, 
201780  
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Gas Analyzer 
Rijkenber
g,  201781  
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Accuracy Arterial, Central 
Venous, or 
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Steil, 201185 
Cardiac 







Arterial by POC and 
Lab  
Prabhudesai, 201586  ICU, n: 19 Guardian 
Medtronic 
MiniMed 
Accuracy Arterial by Lab  
Kotzapanagiotou, 
2019 87 







Arterial by Blood 
Gas Analyzer 
Capillary by POC, 
Biochemical Serum 
by Lab 
Sopfe, 202088  
Stem Cell 
Transplant
ation n: 29 
FreeStyle 





Central Venous by 
Lab 
 1563 



















































Accuracy Capillary by POC  





























































T1DM on CSII 
(n: 1) and 
T2DM on 
basal bolus (n: 
3), COVID-19 
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Table 6. Ongoing hospital CGM studies listed on ClinicalTrials.gov  1566 
Dexcom intervention trial (NCT03877068) 
CGM in Hospitalized Veterans/ Glucose Telemetry System (NCT03508934) 
Scripps Digital Diabetes (NCT04269655) 
Green Line From Hospital to Territory (GreenLightHT) (NCT03764709) 
Use of Wearables for Early Detection of Complications After Major Acute Abdominal Surgery 
(NCT04257344) 
DRIVE—Perioperative Period (DRIVE-Periop) (NCT04033705) 
Flash Glucose Measurement in Patients on Total Parenteral Nutrition (NCT03871660) 
Early Glargine (Lantus) in Diabetic Ketoacidosis Management in Children With Type 1 
Diabetes (NCT03107208) 
Reducing Emergency Department Visits and Improving Glucose Control in Uncontrolled Type 
2 Diabetes Using CGM Sensors at Hospital Discharge (NCT04277780) 
CGM in hospitalized patients with diabetes (NCT04230694) 
Remote Continues Glucose Monitoring During the COVID-19 Pandemic in Quarantined 
Hospitalized Patients (CGM-ISO) (NCT 04430608) 
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The Use of a Continuous Glucose Monitoring System (Dexcom G6) in Hospitalized Patients 
for Acute Care (NCT04385862) 
Wireless Assessment of Respiratory and Circulatory Distress - Continuous Glucose 
Monitoring (WARD-CGM) (NCT04473001) 
Reliability of the Freestyle Libre CGM in the Inpatient Setting During the COVID-19 Surge 
(NCT04417270) 
Table is up-to-date as of August 8, 2020 1567 
Table 7. Contraindications to CSII system and AID system therapy in the hospital 1568 
 1569 
Impaired level of consciousness (except during short-term anesthesia) 
Patient’s inability to correctly demonstrate appropriate CSII system settings 
Critical illness requiring intensive care 
Psychiatric illness that interferes with a patient’s ability to self-manage diabetes 
Diabetic ketoacidosis and hyperosmolar hyperglycemic state 
Refusal or unwillingness to participate in self-care 
Lack of CSII system supplies 
Lack of trained health care providers, diabetes educators, or diabetes specialists 
Patient at risk for suicide 
Health care decision 
Table has been reproduced with permission from Umpierrez and Klonoff, Diabetes Care, 1570 
2018123. “Insulin pump therapy” in the title of the table has been changed to “CSII system and 1571 
AID system therapy”. “Pump” in the second and seventh bullets has been changed to “CSII 1572 
system”. 1573 
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Table 8. CGM data integration complexity across three key domains 1574 
Data Extraction (from 
least to most complex) 
Data Storage (from least to 
most complex) 
Data Display (from least to most 
complex) 
1. Static, standard 
reports 







1. Web storage, linked to 
EHR 
2. Native EHR data tables 
3. External storage and 
computing 
environment 
1. Text and graphic reports 
2. Structured data fields with 
native analytics 
3. Embedded analytics 
displayed from a web 
service 




Table 9. 78 proposed recommendations for the guideline voted on by the panel   1576 
 1577 
Continuation of home Continuous Glucose Monitors after hospitalization 
Clinical Practice: Strong Recommendations 
• HCPs should consult with an inpatient diabetes team if available, when continuing or 
initiating a CGM or AID system. 
• HCPs should avoid relying on CGM data for glycemic management decisions in 
patients with severe hypoglycemia or hyperglycemia (i.e. BG < 40 mg/dL or >500 
mg/dL).  
• HCPs should avoid using CGMs for management of 1) diabetic ketoacidosis until 
glucose is in the CGM measurement range, and then CGMs should be used 
adjunctively or 2) situations with rapidly changing glucose levels and fluid/electrolyte 
shifts. 
• HCPs should avoid continuing or initiating CGMs to patients with skin infections near 
the sensor site or placing sensors in areas with significant edema as well as patients 
treated with vasoactive agents or poor tissue perfusion. 
• HCPs should use a CGM checklist for elective procedures during the pre-operative 
visits to ensure proper documentation of devices and real time data reporting. 
• HCPs should advise pregnant women to continue the use of a CGM during a 
hospitalization to identify glucose trends and prevent hypo- or hyperglycemia. 
• HCPs should instruct patients to bring supplies with them to the hospital for the 
duration of any pre-planned admission or elective procedures. 
• HCPs should check capillary BG or serum BG concentrations after procedures for non-
critically ill patients and venous/arterial blood for critically ill patients to ensure the 
patient’s CGM is functioning properly.   
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• HCPs should use trend arrows and rate of change to help prevent extreme glycemic 
excursions and (when a CGM is used adjunctively) to help determine when a BG test is 
required.   
• HCPs should set alarm thresholds for inpatient glycemic targets, such as predicting 
hypoglycemia (typically BG < 80-85 mg/dL) or predicting hyperglycemia. 
• Nursing should document CGM and/or CSII system information in the electronic 
health record (EHR) for all admissions or elective procedures. 
Research: Strong Recommendations 
• Researchers need to provide more data to support definitive recommendations on 
improved outcomes for continuation of home/ambulatory CGM use after 
hospitalization. 
• Researchers need to conduct studies on the roles of CGM and POC BG testing and 
identify the optimal features of telemetry to inform nursing staff about actionable 
CGM patterns. 
• Researchers need to perform further studies to assess the accuracy of CGMs during 
pregnancy, labor & delivery, and the peripartum period. 
• Researchers need to study the impact of lag time on glucose measurements (i.e. 
situations with rapid changes in the glucose concentration) in the hospital. 
Hospital Policies: Strong Recommendations 
• Hospitals need to develop standard CGM data reports and workflows. 
• Hospitals need to implement policies for testing capillary BGs and calibrating CGMs if 
the CGM requires calibration. 
• Hospitals need to develop a system for automatic staff notification for CGM alarms 
that predict impending or current hypoglycemia or hyperglycemia. 
• Hospitals need to develop specific guidelines for using CGMs and AID systems for 
their affiliated nursing homes and skilled nursing facilities. 
Initiation of Continuous Glucose Monitors after hospitalization 
Clinical Practice: Strong Recommendation Clinical Practice: Mild Recommendation 
• HCPs should consider prescribing 
CGMs to reduce the need for frequent 
nurse contact for POC glucose testing 
and the use of PPE for patients on 
isolation with highly contagious 
infectious diseases (e.g. COVID-19). 
• HCPs should avoid initiating CGMs in 
patients with severe hypoglycemia or 
hyperglycemia (i.e. BG < 40 mg/dL or 
>500 mg/dL) or during periods of 
rapid glucose fluctuations. 
 
Research: Strong Recommendations 
• Researchers need to provide data to support initiation of CGMs for improving patient-
centered outcomes. 
• Researchers need to provide data on hospital outcomes when initiating CGMs in the 
hospital, including improved glycemic outcomes, detection and/or reduction of 
hypoglycemia and hyperglycemia, reduction of ICU LOS, and cost-effectiveness. 
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• Researchers need to conduct studies on long term benefits for initiating CGMs in the 
hospital after discharging patients with newly diagnosed diabetes or recurrence of 
diabetic ketoacidosis (DKA) or other complications of diabetes. 
• Manufacturers need to develop educational tools for patients, hospital staff, and 
HCPs. 
Hospital Policies: Strong Recommendations 
• Hospitals need to develop plans, including process maps, protocols, staff educational 
resources, and order sets for prescribing CGM use during hospitalizations prior to 
implementing a CGM. 
• Hospitals need to provide educational tools for patients, nurses, house staff, and 
attending physicians when a patient in the hospital starts on a CGM.  
Continuation of Automated Insulin Dosing Systems in the hospital  
Clinical Practice: Strong Recommendations Clinical Practice: Mild Recommendation 
• HCPs should prescribe AID systems 
only for appropriate candidates, who 
will need to have adequate knowledge 
and skills for using AID systems. 
• HCPs should reassess a decision 
periodically to transition use of 
outpatient AID systems into the 
hospital in order to ensure that AID 
system continue to represent the best 
treatment option for each patient. 
• HCPs should prepare an alternative 
plan for diabetes management in case 
it becomes inappropriate for a patient 
to continue using an AID system in the 
hospital. 
• HCPs should discontinue AID systems 
in critically ill hospitalized patients 
(such as those with hypovolemia or 
sepsis). 
• HCPs should recognize glycemic 
patterns due to CGM compression, 
which can cause false low readings.  
• HCPs should avoid initiating an AID 
system during a hospitalization. 
 
Research: Strong Recommendations  
• Researchers need to conduct studies about whether continuing AID systems in the 
hospital is beneficial to improve glycemic management or clinical outcomes. 
• Researchers need to provide data on hospital outcomes when using AID systems in 
the hospital, including improved glycemic outcomes, detection and/or reduction of 
hypoglycemia, reduction of ICU LOS, and cost-effectiveness. 
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• Manufacturers need to research whether all types of CGMs and AID systems can be 
used during radiological/imaging studies or diathermy. 
Hospital Policies: Strong Recommendations 
• Hospitals need to develop institution-specific protocols and order sets for the proper 
use of AID systems during a hospitalization. 
• Hospitals need to require that patients using AID systems bring with them sufficient 
supplies for these devices during a hospitalization. 
• Hospitals need to develop protocols for using AID systems during elective procedures 
and surgeries. 
Recommendation Not Reaching Consensus 
• HCPs should switch AID systems from “auto” mode to “manual” mode when a patient 
is admitted to the hospital wearing an AID system. 
Logistics and hands-on care of hospitalized patients using Continuous Glucose 
Monitors and Automated Insulin Dosing Systems 
Clinical Practice: Strong Recommendations 
• HCPs should inquire about and document the medication and supplement history of 
patients who use CGMs to determine whether there are any agents that can interfere 
with glucose measurements. 
• HCPs should ensure that off-label use of CGMs and AID systems is consistent with 
medical practice and appropriate precautions have been taken to protect patients. 
• Nursing should document hands-on training of CGM use and AID system therapy 
through a technology certification program. 
• Nursing should confirm that the patient is appropriate to continue using a CGM or an 
AID system and also review the agreement and hospital policy with the patient. 
• Nursing should inspect the insertion site every shift with attention to skin integrity 
and signs of erythema or infection, and should document site changes. 
• Nursing should know device basics, institutional policies, HCPs roles, and whom to 
contact if questions arise. 
• Nursing should administer a patient competency assessment or survey to assess 
patient ability to safely assist with managing a CGM or an AID system. 
• Nursing should set expectations and clarify that there will be a need to continue 
checking POC capillary glucose even when using a CGM. 
• Nursing should measure POC BG concentrations to confirm or supplement CGM 
readings (usually a minimum of 4 times daily: before each of three meals and at 
bedtime if patients are eating, or every 6 hours if patients are fasting) as well as at 
patient request; however, the CGM glucose, trend arrows, and rate of change may be 
used to help determine if and when a BG test is required. 
Research: Strong Recommendations 
• Researchers need to conduct further studies on the best logistics and hands on care 
for patients using CGMs and AID systems to achieve the best outcomes. 
• Manufacturers need to research interoperable components for AID systems that are 
compatible with hospital EHRs. 
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Hospital Policies: Strong Recommendations 
• Hospitals need to provide interpreter services to translate CGM and AID system 
agreements. 
• Hospitals need to state in their policy and patient agreement documents that 
treatment decisions will be based on hospital-calibrated BGM readings (or laboratory 
readings) and not on CGM readings, barring a need to isolate a patient with a severe 
and highly contagious infection. 
• Hospitals need to maintain their CGM and AID system policy and patient agreement 
documents in easily accessible electronic files stored in the EHR order set for CGMs 
and AID systems. 
• Hospitals need to develop policies for when to discontinue or temporarily suspend 
the use of CGMs and AID systems. 
• Hospitals need to survey their HCPs, nursing, and patients to improve outcomes and 
satisfaction. 
Data management of Continuous Glucose Monitors and Automated Insulin 
Dosing Systems in the hospital 
Clinical Practice: Strong Recommendation Clinical Practice: Mild Recommendation 
• HCPs should develop a set of core 
data elements and definitions for CGM 
data for inclusion in common data 
models and the EHR.  
• Nursing should contact an HCP 
immediately when CGM results cross 
critical value thresholds set by the 
institution. 
Research: Strong Recommendations Research: Mild Recommendation 
• Researchers need to conduct further 
studies on the best data management 
practices of CGMs and AID systems. 
• Researchers need to develop and 
validate robust glucose telemetry 
systems for both ICU and non-ICU 
populations. 
• Researchers need to develop a 
diabetes technology maturity model 
that helps institutions understand the 
requirements to successfully integrate 
diabetes-related data and technology. 
• Researchers need to develop, 
disseminate, and validate CGM- and 
AID system-specific PROs Measures to 
improve patient care. 
• Manufacturers need to research 
methods for quality control for CGMs 
and AID systems, which is critical as 
part of inpatient use of CGMs and AID 
systems. 
• Researchers need to develop 
computerized insulin decision 
support system that will integrate 
with CGMs. 
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• Manufacturers need to research 
optimally expanded device labeling in 
order to overcome clinical inertia and 
align practice with regulatory policy. 
• Manufacturers need to research 
systems for integration of CGM data 
following initial upload into the cloud 
(e.g. the Eversense CGM) 
subsequently into the EHR. 
• Manufacturers need to research 
secure communications systems for 
protecting data from wireless 
wearables, telemedicine systems, and 
Bring-Your-Own-Device portable 
computers used by HCPs (also known 
as “data in motion”). 
Hospital Policies: Strong Recommendations 
• Hospitals need to develop appropriate security protocols, dedicated data storage, 
visualization tools, and adequate cyber insurance coverage (also known as"data at 
rest"). 
• Hospitals need to integrate AID system data into the EHR system for nursing and HCPs 
to have easy access to this information. 
• Hospitals need to determine the number of laboratory or POC BG tests that must be 
performed while patients are using CGMs or AID systems in the hospital. 
• Hospitals need to adopt the UDI (Unique Device Identifier) system for healthcare 
facilities to track devices in the EHR. 
• Hospitals need to identify CGM data reports in the patient’s EHR to distinguish them 
from laboratory glucose results. 
• Hospitals need to present clear criteria to clinicians to identify data that will require 
intervention. 
• Hospitals need to implement CGM- and AID system-specific PROs to improve patient 
care. 
• Hospitals need to develop a universal platform for their EHRs that can be used by all 
CGMs to present core data elements, summary glucometrics, consistent formats, and 
uniform interfaces across all CGM products. 
• Hospitals need to arrange for CGM results to be automatically uploaded into the EHR. 
• Hospitals need to manage CGM data with the same safety and security measures as 
all other PHI. 
• Hospitals need to develop policies for CGM and AID system use with atypical 
scenarios outside of diabetes, when glucose monitoring is valuable. 
 1578 
 1579 
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Figure 1. Continuous Glucose Monitors or Automated Insulin Dosing System Patient Agreement 1580 
I  currently have a continuous glucose monitor and/or 1581 
insulin pump in place and wish to maintain this therapy during my admission to the 1582 
Hospital. I understand and agree as follows: 1583 
 1584 
Patient’s Continuous Glucose Monitor 1585 
1. I may continue to wear my continuous glucose monitor (CGM) during my hospital 1586 
stay but my blood glucose will also be monitored using a hospital-approved blood 1587 
glucose meter and treatment decisions will be based on these results. 1588 
2. I will keep a back-up supply of all CGM supplies including, without limitation, 1589 
sensors and dressings. 1590 
3. I will change the CGM sensor every 7-14 days depending on the device instructions. 1591 
4. I will notify my nurse immediately if my CGM indicates my glucose reading is trending 1592 
out of target (i.e., trending low or high) so that my blood glucose can be tested to 1593 
confirm the trending and appropriate treatment initiated according to the 1594 
prescriber’s order. 1595 
5. I will allow my nurse to assess the sensor site every shift. 1596 
6. If I need any surgery or procedure, then the hospital might need to remove my 1597 
sensor. If I elect to leave my CGM sensor on during any surgery or procedure it may 1598 
present a risk of damage to my CGM sensor during the surgery or procedure. 1599 
7. If I need an MRI scan, then I will remove the sensor prior to the procedure so that 1600 
the transmitter and receiver can be either secured by staff or sent home with a 1601 
designated family member/significant other.  1602 
8. If I need an X-ray or CT scan, then my CGM will be covered by a lead apron.  1603 
9. Any of my CGM supplies stored by hospital staff will be returned to me prior to my 1604 
discharge. 1605 
 1606 
Patient’s Automated Insulin Dosing System  1607 
1. I can manage my own automated insulin dosing system (insulin pump and 1608 
continuous glucose monitors) and the medical condition for which the 1609 
automated insulin dosing system is prescribed. 1610 
a. If my physical or mental condition changes, my caregivers at the hospital may 1611 
re- assess my capability to manage my own pump. If it is determined that I can 1612 
no longer safely manage my pump, the hospital will remove the pump and 1613 
administer insulin by injection or IV as determined by my provider. 1614 
b. Hospital personnel will not operate my pump, except in the above-1615 
described situation. 1616 
2. Only family members/significant others who usually assist me with the operation of 1617 
my pump will do so during my hospital stay. I will keep a back-up supply of all insulin 1618 
pump supplies including, without limitation, insertion sets, infusion tubing and 1619 
dressings. 1620 
3. My insulin will be kept in my personal medication bin and my nurse will get it for 1621 
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me when needed for an insulin infusion set change. 1622 
4. I will change my insulin infusion set every 48-72 hours (2-3 days) or earlier as needed. 1623 
5. If I change my insulin pump settings, I will immediately communicate that with 1624 
my health care team. 1625 
6. I will only make changes to the basal rate, unless in auto mode, after discussion with 1626 
my provider. I will notify my nurse immediately if I have any problem with my insulin 1627 
pump. 1628 
7. If I need any surgery, procedure, radiation therapy, or diagnostic imaging (e.g. MRI or 1629 
x- rays), the hospital may need to disconnect my insulin pump and an alternative 1630 
insulin regimen will need to be prescribed. 1631 
8. If I need diagnostic imaging (e.g. MRI or x-rays), I may need to remove the pump 1632 
prior to the procedure, and it will be secured by staff outside of the imaging area. 1633 
9. Regarding the CGM part of my automated insulin dosing system, if I need an MRI 1634 
scan, then I will remove the sensor prior to the procedure so that the transmitter 1635 
and receiver can be either secured by staff or sent home with a designated family 1636 
member/significant other. If I need an X-ray or CT scan, then my CGM will be 1637 
covered by a lead apron. 1638 
10. The hospital staff will monitor my blood glucose with a hospital-approved blood 1639 
glucose meter. 1640 
11. I will report all bolus doses of insulin to my nurse for documentation purposes. 1641 
12. I will allow my nurse to assess the insertion site every shift. 1642 
13. If my blood glucose values are erratic and cannot be controlled, my insulin pump may 1643 
be discontinued, and an alternative insulin regimen will be provided for me. 1644 
14. Prior to being discharged from the hospital, I will confirm with my nurse that the 1645 
pump is working correctly and that there are no problems with medication delivery or 1646 
the delivery site on my body. In the event that there are problems, they will be 1647 
corrected prior to my discharge from the hospital. 1648 
15. Any of my unused insulin and pump supplies that I have brought with me to the 1649 
hospital will be returned to me prior to my discharge. 1650 
16. My physicians and other health care providers may terminate my use of the insulin 1651 
pump if they observe any contraindication to its use or for any reason that they 1652 
believe medically necessary. 1653 
 1654 
By signing below, I acknowledge that I have read, understood, and agreed to the above and 1655 
that all of my questions have been answered. 1656 
 1657 
Patient Signature: _____________________________________________ 1658 
Nurse/Provider Signature:   __________  1659 
Nurse/Provider Print Name:   ______   1660 
Unit/Service:  _________________________________________________ 1661 
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Date & Time:   __________________________________ 1662 
